1. GMP/Quality issues
Report back from the discussion in last year’s symposium

Mr. Fumihito Takanashi,
Office of International Regulatory Affairs
Ministry of Health, Labour and Welfare (MHLW)

April 24th, 2017
Drug Export from India to Japan (weight)

Source: Directorate General of Commercial Intelligence and Statistics, India
GMP Session at the 1

st

Symposium (May, 2016)
Major points at the 1st Symposium

Mr. Kudo (MHLW)/Mr. Morisue (PMDA)
- Risk-based approach (on-site/desktop inspection)
- International harmonization (ICH, PIC/S)

Dr. Somani (CDSCO)
- Regulation/Inspection procedure/Regulatory Actions
- Practical Aspects: Common deficiencies

Dr. Sanjit Singh Lamba (Eisai-India)
- Quality control in the manufacturing site
- Distinction between the regulatory requirements and business customary requirements

Cooperation started after the 1st Symposium

Agreement at the 1st symposium:

When PMDA conducts GMP on-site inspection for a pharmaceutical manufacturing site in India, based on the coordination with CDSCO in advance, PMDA accepts CDSCO to accompany the inspection as an observer.

On-site learning of GMP inspection methodology
PMDA-Asia Training Center
GMP Inspection Seminar in Toyama (Dec. 2016)

Around 20 inspectors from the world took the GMP course.

FY2017 Plan:
July 31 to August 4
@Yamaguchi prefecture
Registration by May 10
Pharmaceutical GMP system of Japan

Toshiaki KUDO
Compliance & Narcotics Division
Pharmaceutical Safety and Environmental Health Bureau, MHLW Japan

2nd India-Japan Medical Products Regulation Symposium
24th April 2017
Key Elements of Pharmaceutical GMP System

■ Manufacturing Control & Quality Control by Manufacturer

■ Quality Assurance by Marketing Authorization Holder

■ GMP Inspection by Competent Authority
Manufacturing Control & Quality Control by Manufacturer

- Manufacturing of Drugs (including APIs) is basically subject to the GMP Ordinance (MHLW Ministerial Ordinance No. 179, 2004).
  - Applies to manufacturing sites in Japan, but also to foreign manufacturing sites of the products to be exported to Japan.

- The current GMP Ordinance has resulted from comprehensive amendment to the former GMP Ordinance (MHLW Ministerial Ordinance No. 16, 1999), having harmonized with ICH Quality Guidelines.
Manufacturer’s Responsibility

- Besides routine Manufacturing Control & Quality Control, periodic duties for ensuring Product Quality should be undertaken under the manufacturer’s system* for managing quality.

  - **Product Quality Review;**
    Article 5 of the GMP Ordinance, ref. ICH Q7 2.5
  
  - **Periodic Review of Validated Systems;**
    Article 13 of the GMP Ordinance, ref. ICH Q7 12.6
  
  - **Internal Audits (Self Inspection);**
    Article 18 of the GMP Ordinance, ref. ICH Q7 2.4
  
  - **Training;** Article 20 of the GMP Ordinance, ref. ICH Q7 3.1

* ICH Q7 2.11

“Each manufacturer should establish, document, and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.”
Quality Risk Management

- Manufacturer’s Initiative to establish Scientific Evaluation and Management regarding the Manufacturing Process, as one of the components for good Manufacturing Control & Quality Control

- ICH Q9; Quality Risk Management (2005)
  - Provides principles and examples of tools for Quality Risk Management that can be applied to different aspects of pharmaceutical quality
  - Japanese translation of ICH Q9 document (PFSB/ELD (Yakushoku-shinsa) notification No.0901004 and PFSB/CND (Yakushoku-kanma) notification No.0901005) issued on 1st September 2006.
Quality Risk Management

◆ The concept of **Quality Risk Management** has been implemented on manufacturing drugs (including APIs) under GMP Ordinance.

◆ Each Manufacturer is expected to consider **Quality Risk Management** as effective evaluation methods for promoting continuous improvement of the validity of the manufacturing process & the product quality.

➤ For creating and disseminating mock models for good practice of Quality Risk Management, **The Federation of Pharmaceutical Manufacturer’s Associations of Japan (FPMAJ)** have been collaborating with PMDA, supported under a MHLW regulatory science project.
Quality Assurance
by Marketing Authorization Holder
Quality Assurance by Marketing Authorization Holder

*Under Japan’s legislation, implementation of Manufacturing Control & Quality Control at the manufacturing site (including for APIs) is one of the Requirements for Marketing Authorization (MA) of the finished product, in principle.*

- Implementation of Manufacturing Control & Quality Control at the manufacturing site, is undertaken by the manufacturer itself, but also assured under the supervision by the MA holder who entrusts its product manufacturing.
MA Holder’s Responsibility

The Ordinance on Standards for Quality Assurance (the GQP Ordinance, Ministerial Ordinance No. 136, 2004) is enacted as one of the requirements for Licensing of MA Holder.

Key Points of the GQP Ordinance

- Article 5: Quality Standard Code
- Article 7: Agreement with Manufacturers (including Foreign Manufacturers)
- Article 9: Control of Market Release
- Article 10: Ensuring appropriate Manufacturing Control & Quality Control at the Manufacturing Site (including Foreign Manufacturing Site)
- Article 11: Handling Information on Quality, etc. and Quality Defects, etc.
- Article 12: Handling Product Recall
- Article 13: Internal Audit
- Article 14: Training/Education of Personnel
MA Holder’s Responsibility

- Article 7 of the GQP Ordinance;

Key items to conclude an agreement with manufacturers (including foreign manufacturers)

- The nature and extent of the periodic audits by the MA holder, on the manufacturer’s duties which are conducted under the appropriate and efficient manufacturing control & quality control,

- The procedures and the responsible persons to communicate with the MA holder in advance, regarding any change in the production process, testing procedure, etc., in case where such a change may affect the product quality,
MA Holder’s Responsibility

- Article 10 of the GQP Ordinance;
  **Ensuring Proper Manufacturing Control & Quality Control** at the Manufacturing Site (including foreign manufacturing site)

  - **Obtaining relevant information** from the Manufacturer (including Foreign Manufacturer),
  - **Periodic audits (on-site, if necessary)** that the Manufacturing Control & Quality Control is conducted appropriately by the Manufacturer (including Foreign Manufacturer)
Pharmaceutical Quality System
(ICH Q10)

- Applies to the systems supporting the development and manufacture of pharmaceutical drug substances (i.e., API) and drug products, throughout the product lifecycle
- Describes one comprehensive model for an effective Pharmaceutical Quality System that is based on ISO quality concepts, includes applicable GMP regulations and complements ICH Q8 and Q9
Pharmaceutical Quality System
(ICH Q10)

- Three main Objectives
  - Achieve Product Realization
  - Establish and Maintain a State of Control
  - Facilitate Continual Improvement

- Management Responsibility
  - Management Commitment
  - Quality Policy
  - Quality Planning
  - Resource Management
  - Internal Communication
  - Management Review
  - Management of Outsourced Activities and Purchased Materials
  - Management of Change in Product Ownership
GMP Inspection by Competent Authority
Japan’s Competent Authorities

- Compliance & Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW
- Office of Manufacturing/Quality and Compliance, Pharmaceuticals and Medical Devices Agency (PMDA), as National Inspectorate, pursuant to the provision in Article 13-2 paragraph 1 of the PMD Act.
- 47 Prefectural Inspectorates
Respective Duties among Japan’s Inspectorates

◆ PMDA conducts GMP Inspections

➢ At **Foreign Manufacturing Sites**, or
➢ At Domestic Manufacturing Sites, concerning **the drugs (including APIs) requiring special attention in terms of Manufacturing Control & Quality Control**, such as
  ✓ New Drugs
  ✓ Biological Products (Vaccines, Blood products, etc.)
  ✓ Products utilizing Genetical Recombination Technology
  ✓ Products utilizing Cell Culture Technology
  ✓ Radio Pharmaceuticals, etc.

◆ **Prefectural Inspectorates** conduct GMP Inspections at Local Manufacturing Sites in Japan, concerning the products (including APIs) other than above, as of generic drugs, OTC drugs, etc.
Types of GMP Inspection (1)

- **Pre- & Post- Marketing GMP review**
  Conformity Assessment, for which the Marketing Authorization (MA) Holder or the manufacturer make an application regarding their products, pursuant to the provision in Article 14 paragraph 6 or 9 of the PMD Act.
  
  - **Pre-Marketing GMP Review** for MA (including partial change of existing MA)
  
  - **Periodical GMP Review** after MA as a Requirement for Maintaining the MA, at least Once every Five years after MA of the product

- **GMP Conformity Assessment on domestic manufacturing sites concerning of the products to be exported from Japan** where a GMP certificate being requested by foreign government and/or International Organization, for which the manufacturer make an application regarding their products, pursuant to the provision in Article 80 paragraph 1 of the PMD Act.
Types of GMP Inspection (1) (cont.)

◆ Pre- & post- Marketing GMP Review categorized by method
  ➢ On-site Assessment
to be conducted at least Once every Two years approximately in principle, to each manufacturing site

➢ Dossier Assessment (Desk-top Assessment)
may be substituted for the on-site assessment, taking into account of
  ✓ The type of the product to be audited
  ✓ The manufacturing process of the product to be audited
  ✓ The changing history of the manufacturing facilities
  ✓ The results of previous GMP inspections to the site
  ✓ Previous product recall caused by the site, etc.
Types of GMP Inspection (2)

**GMP Surveillance**

to be conducted if needed by relevant Competent Authority, even though not requested by the MA Holder/the Manufacturer, at the manufacturing site, pursuant to the provision in Article 69 or Article 75-4 paragraph 2 of the PMD Act.

- **Usual Surveillance**
  may be conducted without notice, taking into account of the previous GMP deficiencies and/or the degree of requiring Manufacturing Control & Quality Control.

- **Special Surveillance**
  to be conducted without notice, in principle, regarding pernicious non-compliances e.g. fraud etc. (including suspicious cases)
Each inspectorate may conduct a GMP surveillance without notice, regarding the matters which the manufacturer does not anticipate, in the course of the notified GMP Review for which the MA Holder/Manufacturer made an application.
PIC/S
Pharmaceutical Inspection Co-operation Scheme

◆ An International Framework for Cooperation among Competent Authorities responsible for Pharmaceutical Inspection

  ➢ 49 participating authorities from 46 countries/regions (as of January 2017)

◆ Activities;

  i. International Harmonization on Pharmaceutical GMP

  ii. International Cooperation on Pharmaceutical Inspection, such as information sharing and training, etc.
PIC/S
Pharmaceutical Inspection Co-operation Scheme

◆ Japan’s competent authority (MHLW, PMDA and 47 prefectural inspectorates) has become one of PIC/S participating authorities, since July 2014.

➢ As preparatory efforts for accession to PIC/S, Japan’s competent authority upgraded its GMP System, including training/qualification of inspectors of PMDA and 47 prefectural inspectorates, GMP inspection manual, and regular meetings among GMP inspectorates, etc.

● At Pharmaceutical Industries
  ➢ Promoting Quality Risk Management
  ➢ Implementation of Revised Standard on Validation
  ➢ Application of PIC/s GMP Guide, etc.
PIC/S
Pharmaceutical Inspection Co-operation Scheme

◆ International Harmonization on Pharmaceutical GMP

➢ PIC/S GMP Guides

provide various methods to ensure product quality, as useful references for implementing GMP.

✓ Recent Updates; Revised Chapters 1, 2, 6 & 7 of Part I of PIC/S GMP Guide, entered into force on 1st January 2017

● If applicable, each manufacturer is expected to utilize relevant PIC/S GMP Guides as references, on its initiative.

➢ Pharmaceutical Industry GMP Standards

• on Crude Drugs and KANPO Preparations, ref. PIC/S GMP Guide Annex 7
• on Medicinal Gases, ref. PIC/S GMP Guide Annex 6
PIC/S
Pharmaceutical Inspection Co-operation Scheme

◆ International Cooperation on Pharmaceutical Inspection

➢ Procedure to inform Foreign Regulatory Agencies of Foreign Inspections to be conducted in their Jurisdiction

– came into effect since Nov. 2015

– from Inspectorate(s) of the visited country/region

✓ the date of the last inspection

✓ the possibility to share available inspection reports (in the language in which the inspection report was written)

✓ where appropriate, request for opportunities to participate as an observer in the inspection or explore options for that of a joint inspection
Other International Cooperation on Pharmaceutical GMP Inspection

◆ Programme to rationalize international GMP inspections of API manufacturers

➢ Participants;
  Regulatory authorities conducting routine GMP inspections of API manufacturers in foreign countries/regions
  - Authorities in Europe, including EMA and EDQM
  - Authorities in North America; US-FDA and Health Canada
  - Australian TGA
  - WHO, and
  - PMDA Japan (joined since November 2016)

● Sharing information on GMP inspections, including planning and reports of API manufacturers located outside the participating countries.
Thank You for Listening
GMP Inspection by PMDA

Kentaro Hara, Ph.D.
Principal GMP Inspector
Office of Manufacturing/Quality and Compliance
Agenda

1. Risk-based approach
   (On-site inspection or Desk-top inspection )

2. On-site Inspection

3. Observations categorized major deficiencies

4. International Cooperation
   ● API Program
   ● Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)
Agenda

1. Risk-based approach
   (On-site inspection or Desk-top inspection)

2. On-site Inspection

3. Observations categorized major deficiencies

4. International Cooperation
   - API Program
   - Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)
Risk-based approach
(On-site inspection or Desk-top inspection)

Information
- Attached information at GMP application
  1. Information of the product
     (Attachment 1)
  2. Information of the site
     Inspection history
     (Attachment 2: domestic sites)
     (Attachment 3: foreign sites)
- Past inspection
  (Site profile)
  1. Grade of the site
  2. Each sub-system

Data Accumulation

Risk analysis
- Items to be evaluated at risk analysis
  - Sorts of product
  - Manufacturing process
  - Dosage form
  - Inspection history by foreign inspectorates
  - Past GMP non-compliance
  - Past recall history
  - Inspection by PMDA
  - Site information (Previous information)
  - Others

Selection sheet

On-site inspection
Desk-top Inspection
Risk-based decision making cycle

**Risk assessment:**
- Product characteristics
- Process characteristics
- Dosage form
- Inspection history by other authorities
- Inspection report from PIC/S members
- Recall history

**Data base:**
*PMDA inspection history*

**Decision:**
On-site or Desktop

**Update:**
Internal database

**Inspection:**
Ranking based upon assessment of 6 subsystems: S, A, B, C and D
1) Quality systems
2) Facilities & equipment
3) Materials control
4) Production control
5) Packaging & labelling; and
6) Quality control.
Events for on-site inspection

Risk assessment using “Selection Sheet”

- Product characteristics
- Process characteristics
- Dosage form
- Inspection history by other authorities
- Recall history
- Inspection report from PIC/S members

Database: PMDA inspection history

Planning for on-site inspection

Pre-inspection meeting

On-site inspection

Inspection report summary form

Yes, this is on-site.

Checkpoint sheet:
- Define the risk
- Isolate the risk
Using pre-submitted documents from the mfg. site

Receive corrective action report

Send the observations to production site

Inspection report

Post-inspection meeting:
- Site ranked by assessment of 6 subsystems
- Fix the observations
Agenda

1. Risk-based approach
   (On-site inspection or Desk-top inspection)

2. On-site Inspection

3. Observations categorized major deficiencies

4. International Cooperation
   ● API Program
   ● Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)
On-site Inspection by PMDA (2006-2016)
# On-site Inspections in India by PMDA

PMDA’s Overseas On-Site Inspection / On-Site Inspection to Manufacturing Sites in India

<table>
<thead>
<tr>
<th>Total number of On-Site Inspection (Overseas)</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>61</td>
<td>65</td>
<td>66</td>
<td>71</td>
<td>65</td>
<td>79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of On-Site Inspection in India ◆</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Site Evaluation : C/D)</td>
<td>4 (0/0)</td>
<td>4 * (0/2)</td>
<td>2 (0/1)</td>
<td>2 (0/0)</td>
<td>20 (5/0)</td>
<td>18 (3/0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>India / Total (%)</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7%</td>
<td>6%</td>
<td>3%</td>
<td>3%</td>
<td>31%</td>
<td>23%</td>
</tr>
</tbody>
</table>

◆Manufacturing Sites were graded as S,A,B,C,D according to PMDA's On-Site Inspection

* D : Manufacturers in non-compliance with GMP
* C: Manufacturers in compliance with GMP but needed to be given continuous instructions

As of 12 Apr. 2017
Agenda

1. Risk-based approach
   (On-site inspection or Desk-top inspection )

2. On-site Inspection

3. Observations categorized major deficiencies

4. International Cooperation
   - API Program
   - Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)
### Observations categorized major deficiencies

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validation</td>
<td>35</td>
<td>Validation</td>
<td>33</td>
</tr>
<tr>
<td>Document Control</td>
<td>34</td>
<td>Document Control</td>
<td>25</td>
</tr>
<tr>
<td>Cross Contamination / Containment</td>
<td>24</td>
<td>Deviation Control</td>
<td>19</td>
</tr>
<tr>
<td>Deviation Control</td>
<td>18</td>
<td>Cross Contamination / Containment</td>
<td>13</td>
</tr>
<tr>
<td>Quality control of materials</td>
<td>10</td>
<td>Change Control</td>
<td>11</td>
</tr>
<tr>
<td>Quality Risk Management</td>
<td>9</td>
<td>Manufacturing Procedure</td>
<td>7</td>
</tr>
<tr>
<td>Equipment (IQ,OQ,PQ. Daily Check, Calibration)</td>
<td>7</td>
<td>Equipment (IQ,OQ,PQ. Daily Check, Calibration)</td>
<td>5</td>
</tr>
<tr>
<td>Training</td>
<td>5</td>
<td>Training</td>
<td>5</td>
</tr>
<tr>
<td>Release</td>
<td>5</td>
<td>Cleaning Validation</td>
<td>5</td>
</tr>
</tbody>
</table>
Which documents should we check?

Life Cycle Management

Develop/Improve the process

Transfer (R&D to Production)

Production of commercial batches

Validation Master Plan

Tech. Transfer Protocol & Report

CPV Protocol

Gap Analysis (Scale, Equipment...)

PQ Protocol & Report

Risk Management

PV Protocol & Report

Deviations

Quality System
Appropriate containment measures and controls include but are not limited to the following:

【①Hard】
Technical controls (e.g., dedicated production areas, closed/dedicated Heating Ventilation and Air Conditioning (HVAC) system, closed manufacturing systems, use of disposable technologies, design of facility and equipment for containment and ease of cleaning)

【②SOPs】
Procedural (organisational) controls (e.g., cleaning, personnel flow, environmental monitoring and training)

【③Monitoring】
Monitoring systems are important to check the effectiveness of the containment controls.

(Reference: ICH Q7 Q&As)
Knowledge management cycle

Periodic (Daily...) monitoring
PQR

Production

Change control

Vision

Information

Data

Knowledge

Validity

Deviation/OOS

Prospective process validation

CAPA

Quality management system

Knowledge management cycle into the production site (R&D⇔Production)

Information from outside (customers...)

Complaint

Data

Information

Knowledge

Data

Information

Data
Practical models and tools for Quality system and Quality Risk Management

SOPs for Quality System

Conceptual Diagram for QRM

Example of QRM

Target of QRM

Example of QRM (Risk assessment Sheet)
Agenda

1. Risk-based approach
   (On-site inspection or Desk-top inspection)

2. On-site Inspection

3. Observations categorized major deficiencies

4. International Cooperation
   ● API Program
   ● Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)
The primary responsibility of the Pharmaceuticals and Medical Devices Agency (PMDA) is to provide a reliable regulatory environment that enables quicker access to more effective and safer medical products including pharmaceuticals, medical devices, and cell-based and tissue-based products for the people of Japan. Regulatory science forms the basis of PMDA’s activities. As the development, manufacture, and distribution of products are becoming increasingly globalized, PMDA must increase its efforts to cooperate closely with foreign regulatory authorities, as well as industry and academia, in order to meaningfully contribute to the health and healthy life expectancy of the people in Japan and globally.

In view of the aforementioned situation as well as the Regulatory Strategy Initiative set forth by the Ministry of Health, Labour and Welfare (MHLW) in June 2015, PMDA has established the following strategic plan on international activities that will be conducted in the period defined in the 3rd Midterm Plan (FY 2014–2022). PMDA will strive to implement the strategies that maximizes the health benefits to Japan and the world, by effectively utilizing scientific knowledge, electronic information, and human resources.
## Roadmaps to implement Strategy 3

<table>
<thead>
<tr>
<th>GMP</th>
<th>Increase efficiency of inspections</th>
<th>QMS</th>
<th>GLP</th>
<th>GCP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3&lt;sup&gt;rd&lt;/sup&gt; Mid-term Plan</strong></td>
<td><strong>4&lt;sup&gt;th&lt;/sup&gt; Mid-term Plan</strong></td>
<td><strong>3&lt;sup&gt;rd&lt;/sup&gt; Mid-term Plan</strong></td>
<td><strong>4&lt;sup&gt;th&lt;/sup&gt; Mid-term Plan</strong></td>
<td><strong>3&lt;sup&gt;rd&lt;/sup&gt; Mid-term Plan</strong></td>
</tr>
<tr>
<td>In 3 yrs.</td>
<td>In 5 yrs.</td>
<td>In 3 yrs.</td>
<td>In 5 yrs.</td>
<td>In 3 yrs.</td>
</tr>
</tbody>
</table>

### GMP
- Strengthen PIC/S activity
- Conduct co-trainings and inspections with Asian Regulatory Authorities
- Review report exchanges
- Take steps towards MRA sign-offs

### QMS
- Promote up-skilling of inspections / conduct co-inspections
- Strengthen MDSAP activity
- Review report exchanges

### GLP
- Actively lead OECD/GLP as a chair
- Promote equalisation of inspection skills within OECD

### GCP
- Plan a model for mutual use of US/EU/Japan inspection results
- Conduct workshops in emerging countries, and promote mutual acceptance of inspection results
- Set up a platform for GCP cooperation
Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC)

Practical training in the form of a mock inspection with the support of Japan Pharmaceutical Manufacturers Association (JPMA) and PIC/S.
Dec. 2016 at Toyama, Japan

- Planning of inspection based on risk
- Risk of Quality
- Data Integrity

- Upskilling of GMP inspectors in Asia
- Harmonize the procedure of GMP inspection

- Improvement of GMP level of manufacturing site in Asia
Programme to rationalize international GMP inspections of API manufacturers

- Participants; Regulatory authorities conducting routine GMP inspections of API manufacturers in foreign countries/regions
  - Authorities in Europe, such as European Medicines Agency (EMA), EU Member States, and European Directorate for Quality of Medicines & Healthcare (EDQM)
  - Authorities in North America; US-FDA and Health Canada,
  - Australian Therapeutic Goods Administration (TGA),
  - World Health Organization (WHO), and
  - **PMDA Japan** (joined since November 2016)

- Sharing information on GMP inspections, including planning and reports of API manufacturers located outside the participating countries.
"PMDA-ATC GMP Inspection Seminar 2017" for GMP inspectors from overseas regulatory authorities.

This Seminar will be held in Yamaguchi prefecture, Japan, from July 31 to August 4, 2017.

The primal object of this Seminar will be Risk-based Inspection and Data Integrity.

Registration will close on May 10, 2017.

http://www.pmda.go.jp/english/symposia/0107.html
Thank you for your attention.